NeuMoDx COVID-19 multiplex test gets EUA

July 2021—Qiagen announced FDA emergency use authorization for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay, to help identify and differentiate people suspected of respiratory viral infection consistent with COVID-19.

The multiplex PCR test detects and differentiates influenzas A and B, respiratory syncytial virus, and SARS-CoV-2 infections within 80 minutes.

Qiagen launched the test in November in the European Union and other markets that accept CE-IVD and will begin commercialization of the test in the U.S.

Qiagen, 800-426-8157